|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400093782 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-11 17:45:10 |
|
注册时间: Date of Registration: |
2024-12-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
经皮微球囊压迫治疗原发性三叉神经痛安全性和有效性的临床观察 |
|
Public title: |
Clinical observation on the safety and efficacy of percutaneous microballoon compression for the treatment of primary trigeminal neuralgia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
经皮微球囊压迫治疗原发性三叉神经痛安全性和有效性的临床观察 |
|
Scientific title: |
Clinical observation on the safety and efficacy of percutaneous microballoon compression for the treatment of primary trigeminal neuralgia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘宇 |
研究负责人: |
王长明 |
|
Applicant: |
Liu Yu |
Study leader: |
Wang Changming |
|
申请注册联系人电话: Applicant telephone: |
+86 131 6557 2711 |
研究负责人电话:
Study leader's |
+86 177 0248 6100 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2974428340@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
TeamWangCM@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
辽宁省沈阳市沈河区文艺路33号 |
研究负责人通讯地址: |
辽宁省沈阳市沈河区文艺路33号 |
|
Applicant address: |
No. 33, Wenyi Road, Shenhe District, Shenyang City, Liaoning Province |
Study leader's address: |
No. 33, Wenyi Road, Shenhe District, Shenyang City, Liaoning Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
辽宁省人民医院 |
||
|
Applicant's institution: |
Liaoning Provincial People's Hospital |
||
|
研究负责人所在单位: |
辽宁省人民医院 |
||
|
Affiliation of the Leader: |
Liaoning Provincial People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2024)H056号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
辽宁省人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Liaoning Provincial People's Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-11-20 00:00:00 | ||
|
伦理委员会联系人: |
郑凯 |
||
|
Contact Name of the ethic committee: |
Zheng Kai |
||
|
伦理委员会联系地址: |
辽宁省沈阳市沈河区文艺路33号 |
||
|
Contact Address of the ethic committee: |
No. 33, Wenyi Road, Shenhe District, Shenyang City, Liaoning Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 24 2401 6355 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
辽宁省人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Liaoning Provincial People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
辽宁省沈阳市沈河区文艺路33号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 33, Wenyi Road, Shenhe District, Shenyang City, Liaoning Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
原发性三叉神经痛 |
||||||||||||||||||||||
|
Target disease: |
Primary trigeminal neuralgia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
探究性别、年龄、复发性三叉神经痛患者的手术类型对经皮微球囊压迫治疗原发性三叉神经痛的安全性和有效性的影响以及经皮微球囊压迫治疗原发性三叉神经痛患者对其焦虑和抑郁的影响 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the impact of gender, age, and types of surgery of recurrent trigeminal neuralgia on the safety and efficacy of percutaneous microballoon compression for primary trigeminal neuralgia, as well as the impact of percutaneous microballoon compression on anxiety and depression in patients with primary trigeminal neuralgia |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.自2024年12月至2025年12月于辽宁省人民医院接受PBC治疗的临床诊断为原发性TN的患者; 2.纳入患者年龄:18岁≤年龄≤85岁; 3.症状持续时间≥3个月,且至少持续至调查前1周; 4.能够沟通,愿意接受答卷及电话随访者。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients with a clinical diagnosis of primary TN who received PBC treatment at the Liaoning Provincial People's Hospital from December 2024 to 2025 2.Enrolled patient age: 18 years <= age <= 85 years; 3.The duration of symptoms is >=3 months, and lasts at least until 1 week before the investigation; 4.Able to communicate, willing to accept questionnaires and phone follow-ups. |
||||||||||||||||||||||
|
排除标准: |
1. 诊断为继发性 TN 的患者; 2. 无法理解和回答问卷的患者; 3. 患有慢性衰弱和危及生命的疾病或其他形式慢性疼痛的患者; 4. 在首次出现 TN 之前诊断为精神障碍的患者; 5. 未能获得患者或其监护人的知情同意。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients diagnosed with secondary TN; 2.Patients unable to understand and respond to the questionnaire; 3.Patients with chronic debility and life-threatening illnesses or other forms of chronic pain; 4.Patients diagnosed with mental disorders before the first occurrence of TN; 5.Informed consent from the patient or their guardian could not be obtained. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-16 00:00:00至 To 2026-06-16 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-12-16 00:00:00 至 To 2025-12-16 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
ResMan |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
ResMan |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |